Serum Levels Of LTB4and Clinical Analysis Of Treatment In Henoch-Schorlein Purpura Children

Objective:To observe the leukotriene B4level in anaphylactoid purpura(HSP) children, and the serum leukotriene B4level changes and clinicaleffects after the treatment of the Leukotriene receptor antagonists-montelukast, and to observed correlation of hormones and the level ofleukotriene B4.Methods:43cases of HSP were randomly divided into four groups. The6cases in control group were treated with conventional therapy whichadopted vitamin C, calcium, antihistamines, and other drugs, in thehormone group,14cases were treated with hormone and6cases weretreated with montelukast in montelukast group,in combined treatmentgroup,17cases were treated with hormone and montelukast. The dosesof montelukast were different according to the ages, such as2mg/din <2years old cases,4mg/d in2to5-year-old cases,5mg/d in5to10-year-old cases, and10mg/d in10-year-old cases. The course oftreatment was7days for1time daily at bedtime. There were10patientsin normal group without any infections. We detected the serum level ofleukotriene B4in the normal group, the control group,the hormone group,themontelukast group and the combined treatment group before and after the treatment to observe the clinical effects of montelukast. We try to compare theserum leukotriene B4level changes and clinical effects between the cases inusing glucocorticoid and using glucocorticoid and montelukast.Results: Serum leukotriene B4level in HSP cases was significantly higherthan the normal group (P <0.01); the leukotriene levels in children of thetreatment group and the control group were decreased (P <0.01) after thetreatment; compare with the control group, the serum leukotriene B4levels ofthe hormone group (P <0.05).In hormone group,4cases were cured,6caseswere effective,4cases were ineffective, total effective rate was71.5%;Incombination therapy group,4cases were cured,,11cases were effective,2cases were ineffective,the total efficiency of88.2%.Comparing the twogroups, combination therapy is better than monotherapy (P>0.05).Conclusion:1.Serum leukotriene B4participated in the pathogenesis of HSP.2.Oral montelukast treatment in HSP is effective.3.Hormones can reduce the serum levels of LTB4.4.Montelukast combined hormone therapy of the HSP are better than thehormone therapy alone.